Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHAin vitroandin vivo

Targeting Histone Deacetylases in Diseases: Where Are We?

(2015) Rosaria Benedetti et al.   ANTIOXIDANTS & REDOX SIGNALING

The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells

(2013) N Garnier et al.   LEUKEMIA

The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells

(2012) Man-Tat Lau et al.   CANCER LETTERS

Celastrol decreases specificity proteins (Sp) and fibroblast growth factor receptor-3 (FGFR3) in bladder cancer cells

(2012) Gayathri Chadalapaka et al.   CARCINOGENESIS

NF-κB and the link between inflammation and cancer

(2012) Joseph A. DiDonato et al.   IMMUNOLOGICAL REVIEWS

Upregulating Noxa by ER Stress, Celastrol Exerts Synergistic Anti-Cancer Activity in Combination with ABT-737 in Human Hepatocellular Carcinoma Cells

(2012) Hong Zhu et al.   PLoS One

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim

(2011) Yun Dai et al.   BRITISH JOURNAL OF HAEMATOLOGY

GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1

(2011) Lin Zheng et al.   CANCER LETTERS

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer

(2011) Ali Aghdassi et al.   GUT

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

(2011) Kenichi Suda et al.   Journal of Thoracic Oncology

Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

(2011) B. B. Friday et al.   NEURO-ONCOLOGY

E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression

(2011) M-T Lau et al.   ONCOGENE

E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells

(2011) Jan Theys et al.   RADIOTHERAPY AND ONCOLOGY

Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway

(2010) X. Pang et al.   CANCER RESEARCH

Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance

(2010) Wenlin Shao et al.   INTERNATIONAL JOURNAL OF CANCER

Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin

(2010) Akiko Hayashi et al.   INTERNATIONAL JOURNAL OF CANCER

Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway

(2010) Roberto R. Rosato et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Targeting histone deacetylases: development of vorinostat for the treatment of cancer

(2010) Victoria M Richon   Epigenomics

The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma

(2009) Di He et al.   BMC CANCER

Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol

(2009) Hong Zhu et al.   CANCER INVESTIGATION

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Biomarkers for epithelial-mesenchymal transitions

(2009) Michael Zeisberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells

(2008) G E Konecny et al.   BRITISH JOURNAL OF CANCER

Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy

(2008) Stuart Thomson et al.   CLINICAL & EXPERIMENTAL METASTASIS

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study

(2008) Susan C. Modesitt et al.   GYNECOLOGIC ONCOLOGY

A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells

(2008) T. Zhang et al.   MOLECULAR CANCER THERAPEUTICS